mazdutide vs survodutide

NCT05607680 · Phase 3 · completed

The trial was randomized, blinded, and placebo-controlled with over 600 participants, and its primary endpoint was percent body-weight change, a disease-defining measure for obesity. Both mazdutide doses produced significantly greater weight loss than placebo (P<0.0001).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT06077864 · Phase 3 · completed

The study randomly assigns 5,531 participants to two survodutide doses or placebo and uses quadruple blinding. Its primary endpoint is a hard clinical composite of cardiovascular death, nonfatal stroke, nonfatal heart attack, coronary revascularization, or heart-failure events, but the non-inferiority result is not yet available.

NCT05606913 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial of 731 people with type 2 diabetes. Both mazdutide doses lowered blood sugar (HbA1c) significantly more than the comparator drug dulaglutide, a difference that reached statistical significance.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT06066528 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 755 participants, and its primary endpoints were clinical weight-loss measures at Week 76. Because no results are posted, it cannot establish whether the primary endpoints were met.